EDIT Editas Medicine, Inc. - Common Stock
$2,90
Fiyat · Ağu 18, 2026
Temel veriler itibarıyla Ağu 5, 2026
52 Haftlık Aralık
$2–$5
43% of range
Analist Derecelendirmesi
BUY
18 analysts
Fiyat Hedefi
$6
+107% upside
P/E (TTM)
-1.6
ROE
-688.8%
Net Kâr Marjı
-395.0%
Editas Medicine, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Devamını oku
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
EDIT Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$2.90
Piyasa Değeri
$284M
P/E (TTM)
-1.6
EPS (TTM)
$-1.80
Gelir (TTM)
$41M
Temettü Verimi
—
ROE
-688.8%
D/E Borç/Özsermaye
2.1
52 Haftlık Aralık
$2 – $5
EDIT Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$41M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-1.80
2019-12-31
→
2025-12-31
Serbest Nakit Akışı
$-166M
2016-12-31
→
2025-12-31
Marjlar
-395.0%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
EDIT
Akran Ortalaması
P/E (TTM)
-1.6
17.4
P/S (TTM) (F/S (TTM))
7.0
52.3
P/B (F/D)
10.4
4.8
EV / EBITDA
-1.2
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
-1.7
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
EDIT
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-394.9%
—
Net Profit Margin (Net Kâr Marjı)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
EDIT
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
2.1
—
Current Ratio (Cari Oran)
3.5
7.7
Quick Ratio (Cari Oran)
3.5
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
EDIT
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
25.4%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
27.2%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
-14.9%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
EDIT
Akran Ortalaması
EDIT Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
18 analist
- Güçlü Al 4 22,2%
- Al 8 44,4%
- Tut 4 22,2%
- Sat 2 11,1%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
8 analist · 2026-08-16
Medyan
$5.00
Şimdi
$2.90
Düşük
$1.00
Yüksek
$15.00
Medyan hedef
$5.00
+72,4%
Ortalama hedef
$6.00
+106,9%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.03%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 Mart 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 Aralık 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 Eylül 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 Haziran 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 Mart 2025 | $-0.92 | $-0.60 | -0.32% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 13
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Bilanço 24
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Nakit Akışı 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Kârlılık 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Likidite ve Solventlik 4
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Gelir Tablosu 12
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Bilanço 24
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Nakit Akışı 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Kârlılık 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Likidite ve Solventlik 4
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Değerleme (TTM) 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $41M | $32M | $78M | $20M | $26M |
| Faaliyet Kâr Marjı % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Net Gelir | $-160M | $-237M | $-153M | $-220M | $-193M |
| Seyreltilmiş Hisse Başı Kâr | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 2.1 | 0.4 | — | — | — |
| Cari Oran | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Cari Oran | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-166M | $-219M | $-137M | $-181M | $-172M |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 239 dosya · $327.2M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 41 (+2 önceki Ç'ye göre) | 22 (-4 önceki Ç'ye göre) | 76 (+20 önceki Ç'ye göre) | 42 (-9 önceki Ç'ye göre) | +75.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 11,00% | Hisse senetleri |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 8,80% | Hisse senetleri |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 8,80% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 8,80% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 6,08% | Hisse senetleri |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 5,53% | Hisse senetleri |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,82% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 3,56% | Hisse senetleri |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 3,52% | Hisse senetleri |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 3,52% | Hisse senetleri |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 3,10% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 2,45% | Hisse senetleri |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 2,20% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $7.134.030 | 2.201.290 | 2,18% | Hisse senetleri |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 2,17% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $6.763.843 | 2.087.606 | 2,07% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,32% | Hisse senetleri |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,32% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $4.201.156 | 1.296.653 | 1,28% | Hisse senetleri |
| MARSHALL WACE, LLP | $4.044.048 | 1.248.163 | 1,24% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $3.715.178 | 1.146.660 | 1,14% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 1,02% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,87% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,86% | Hisse senetleri |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,84% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,77% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,74% | Hisse senetleri |
| BlackRock, Inc. | $1.813.920 | 559.852 | 0,55% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,49% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,47% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,46% | Alım opsiyonu |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,45% | Hisse senetleri |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,44% | Hisse senetleri |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,41% | Hisse senetleri |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,40% | Alım opsiyonu |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,32% | Hisse senetleri |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,30% | Hisse senetleri |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,27% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,23% | Hisse senetleri |
| LPL Financial LLC | $748.813 | 231.115 | 0,23% | Hisse senetleri |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,22% | Hisse senetleri |
| IEQ CAPITAL, LLC | $705.623 | 217.785 | 0,22% | Hisse senetleri |
| Walleye Capital LLC | $595.703 | 183.859 | 0,18% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558.900 | 172.500 | 0,17% | Satım opsiyonu |
| CITADEL ADVISORS LLC | $557.604 | 172.100 | 0,17% | Satım opsiyonu |
| DAFNA Capital Management LLC | $552.323 | 170.470 | 0,17% | Hisse senetleri |
| Mariner, LLC | $548.500 | 169.291 | 0,17% | Hisse senetleri |
| Green Alpha Advisors, LLC | $505.589 | 156.046 | 0,15% | Hisse senetleri |
| PEAK6 LLC | $497.340 | 153.500 | 0,15% | Alım opsiyonu |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490.555 | 151.406 | 0,15% | Hisse senetleri |
| BARCLAYS PLC | $476.030 | 146.923 | 0,15% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $464.187 | 187.930 | 0,14% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445.030 | 137.355 | 0,14% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408.240 | 126.000 | 0,12% | Hisse senetleri |
| Point72 Asset Management, L.P. | $405.758 | 125.234 | 0,12% | Hisse senetleri |
| RHUMBLINE ADVISERS | $380.421 | 117.417 | 0,12% | Hisse senetleri |
| JPMORGAN CHASE & CO | $376.528 | 117.665 | 0,12% | Hisse senetleri |
| JANE STREET GROUP, LLC | $374.473 | 115.578 | 0,11% | Hisse senetleri |
| FMR LLC | $348.384 | 107.526 | 0,11% | Hisse senetleri |
| HSBC HOLDINGS PLC | $314.481 | 97.062 | 0,10% | Hisse senetleri |
| Bank of New York Mellon Corp | $309.378 | 95.487 | 0,09% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $303.462 | 93.661 | 0,09% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300.818 | 92.845 | 0,09% | Hisse senetleri |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300.226 | 92.094 | 0,09% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $300.011 | 92.596 | 0,09% | Hisse senetleri |
| CWM, LLC | $259.352 | 105.001 | 0,08% | Hisse senetleri |
| MORGAN STANLEY | $237.324 | 73.248 | 0,07% | Hisse senetleri |
| CITADEL ADVISORS LLC | $229.392 | 70.800 | 0,07% | Alım opsiyonu |
| OSAIC HOLDINGS, INC. | $222.928 | 68.806 | 0,07% | Hisse senetleri |
| SEI INVESTMENTS CO | $221.188 | 68.268 | 0,07% | Hisse senetleri |
| Nuveen, LLC | $221.188 | 68.268 | 0,07% | Hisse senetleri |
| Joel Isaacson & Co., LLC | $220.787 | 68.144 | 0,07% | Hisse senetleri |
| JANE STREET GROUP, LLC | $218.376 | 67.400 | 0,07% | Satım opsiyonu |
| SIMPLEX TRADING, LLC | $207.275 | 63.974 | 0,06% | Hisse senetleri |
| MetLife Investment Management, LLC | $182.140 | 56.216 | 0,06% | Hisse senetleri |
| CITIGROUP INC | $182.052 | 56.189 | 0,06% | Hisse senetleri |
| CITADEL ADVISORS LLC | $173.923 | 53.680 | 0,05% | Hisse senetleri |
| MML INVESTORS SERVICES, LLC | $168.765 | 52.088 | 0,05% | Hisse senetleri |
| GROUP ONE TRADING LLC | $163.131 | 50.349 | 0,05% | Hisse senetleri |
| Creative Planning | $147.653 | 45.572 | 0,05% | Hisse senetleri |
| China Universal Asset Management Co., Ltd. | $143.934 | 44.424 | 0,04% | Hisse senetleri |
| WINTON GROUP Ltd | $141.588 | 43.700 | 0,04% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $138.876 | 42.863 | 0,04% | Hisse senetleri |
| CANADA PENSION PLAN INVESTMENT BOARD | $137.376 | 42.400 | 0,04% | Hisse senetleri |
| Graham Capital Management, L.P. | $134.369 | 41.472 | 0,04% | Hisse senetleri |
| Quinn Opportunity Partners LLC | $129.600 | 40.000 | 0,04% | Hisse senetleri |
| Invesco Ltd. | $128.178 | 39.561 | 0,04% | Hisse senetleri |
| Vanguard Personalized Indexing Management, LLC | $124.108 | 38.305 | 0,04% | Hisse senetleri |
| MERCER GLOBAL ADVISORS INC /ADV | $121.967 | 37.644 | 0,04% | Hisse senetleri |
| Balyasny Asset Management L.P. | $121.947 | 37.638 | 0,04% | Hisse senetleri |
| AXQ CAPITAL, LP | $118.104 | 36.452 | 0,04% | Hisse senetleri |
| Nuveen Asset Management, LLC | $113.934 | 89.712 | 0,03% | Hisse senetleri |
| SCS Capital Management LLC | $113.400 | 35.000 | 0,03% | Hisse senetleri |
| Police & Firemen's Retirement System of New Jersey | $109.749 | 33.873 | 0,03% | Hisse senetleri |
| Thrive Wealth Management, LLC | $108.540 | 33.500 | 0,03% | Hisse senetleri |
| TWO SIGMA SECURITIES, LLC | $107.367 | 33.138 | 0,03% | Hisse senetleri |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102.359 | 31.207 | 0,03% | Hisse senetleri |
| CAPTRUST FINANCIAL ADVISORS | $98.159 | 30.296 | 0,03% | Hisse senetleri |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89.683 | 27.680 | 0,03% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88.339 | 27.265 | 0,03% | Hisse senetleri |
Şirket yöneticileri 32 içeriden öğrenenler · 13 yöneticiler · 15 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 03 Haziran 2026 S | 248.313 | 0 | 1 | $-41.543 |
| MULLEN JAMES C | CEO | 03 Ocak 2022 S | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 09 Şubat 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 08 Ocak 2019 S | 1.204.966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 Ocak 2022 S | 31.462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 04 Şubat 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 Temmuz 2026 S | 62.369 | 0 | 2 | $-15.133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 Aralık 2021 A | 31.498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 Aralık 2021 A | 22.675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 Aralık 2021 A | 41.785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 Ekim 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 Mart 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 07 Şubat 2018 A | 4.000 | 0 | 0 | $0 |
| Elliott M. Levy | Yönetim kurulu üyesi | 17 Haziran 2026 A | — | 0 | 0 | $0 |
| David Scadden | Yönetim kurulu üyesi | 17 Haziran 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Yönetim kurulu üyesi | 17 Haziran 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Yönetim kurulu üyesi | 17 Haziran 2026 A | 22.700 | 0 | 0 | $0 |
| Andrew Hirsch | Yönetim kurulu üyesi | 17 Haziran 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Yönetim kurulu üyesi | 03 Eylül 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Yönetim kurulu üyesi | 03 Haziran 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Yönetim kurulu üyesi | 15 Haziran 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Yönetim kurulu üyesi | 17 Ağustos 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Yönetim kurulu üyesi | 15 Haziran 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Yönetim kurulu üyesi | 15 Haziran 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Yönetim kurulu üyesi | 15 Haziran 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | 10% sahip | 06 Eylül 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10% sahip | 08 Şubat 2016 C | 2.649.572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 06 Ağustos 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 03 Ağustos 2026 S | 14.292 | 0 | 2 | $-3.002 |
| Akshay Vaishnaw | — | 03 Haziran 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 Aralık 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 Mart 2017 M | 117.788 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 başvurular | 18 Eylül 2017 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 28 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32.319 SH | 08 Ağustos 2026 | Günlük |
| GNOM · Global X Funds | 0,34% | 54.725 NS | 31 Mayıs 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341.978 SH | 08 Ağustos 2026 | Günlük |
| IBB · iShares Trust | 0,03% | 1.035.067 SH | 08 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8.268 SH | 08 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 08 Ağustos 2026 | Günlük |
| BIB · ProShares Trust | 0,02% | 3.611 NS | 31 Mayıs 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1.527 NS | 31 Mayıs 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823.535 SH | 08 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118.938 SH | 08 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 08 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 08 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,01% | 2.583.050 SH | 08 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 42.610 NS | 30 Nisan 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4.633 NS | 31 Mayıs 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476.309 NS | 31 Mayıs 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3.622 NS | 31 Mayıs 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32.379 NS | 31 Mayıs 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3.660 NS | 31 Mayıs 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120.119 SH | 08 Ağustos 2026 | Günlük |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 Mayıs 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2.922 NS | 31 Mayıs 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96.350 NS | 31 Mayıs 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.020 SH | 08 Ağustos 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 08 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 08 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 08 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 08 Ağustos 2026 | Günlük |